01 /What TB-500 is
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a naturally occurring 43 amino acid protein found in most cell types. Specifically, TB-500 is a 7 amino acid fragment (LKKTETQ) corresponding to residues 17 to 23 of the full Thymosin Beta-4 sequence, or in some commercial preparations a closely related fragment.
The full Thymosin Beta-4 protein is also commercially synthesized and listed separately in the Apothify library. TB-500 the fragment and Thymosin Beta-4 the full protein are different molecules with overlapping but not identical research profiles.
02 /What the research literature describes
Thymosin Beta-4 is one of the most studied natural peptides in cell biology. It functions in normal physiology as the major intracellular G actin sequestering protein, which means it binds and stores actin monomers in a form that can be rapidly released for actin polymerization when needed. This actin sequestration role is fundamental to cell motility, cytoskeletal dynamics, and wound recovery research.
Published research on Thymosin Beta-4 and on the TB-500 fragment spans cell motility studies, angiogenesis research, cardiac tissue research in animal models, corneal and ocular tissue research, and dermatological research. Several clinical research programs in different disease contexts have moved through early phase trials.
03 /TB-500 vs Thymosin Beta-4
Both compounds appear in the Apothify library as separate entries. Thymosin Beta-4 is the full 43 amino acid protein; TB-500 is the 7 amino acid LKKTETQ active fragment.
In practice, much of the published research uses the full protein. TB-500 as a research peptide is more commonly used in non clinical research settings where the smaller fragment is easier to source and handle.
The Apothify interaction matrix considers them overlapping; the compare tool will surface a redundant flag if you put them side by side. There is no clear research rationale for combining them.
04 /Why TB-500 is ELEVATED in the Apothify library
TB-500 is classified ELEVATED in the Apothify library. The encyclopedia entry exists; there is no cart pathway, no checkout, and no price.
The regulatory rationale is similar to BPC-157. TB-500 has been the subject of compounding pharmacy scrutiny and is in the same general category of research peptides that the FDA has flagged through the 503A process. WADA has also addressed Thymosin Beta-4 and its fragments in its prohibited list for competitive sport contexts.
Apothify's product gate excludes compounds in this regulatory category from commerce. The encyclopedia entry exists for library completeness.
05 /Common pairings in the research literature
TB-500 is commonly compared with BPC-157 in tissue recovery research contexts. The mechanisms are different (TB-500 through actin and angiogenesis pathways; BPC-157 through multiple parallel pathways), but the research framing overlaps. Both are ELEVATED in the library.
Combinations with growth factor signaling compounds are described in the literature in animal models. The Apothify interaction matrix does not flag specific pairings beyond the BPC-157 comparison.
06 /What the safety section actually says
The Apothify safety section on TB-500 states that combinations with other recovery focused research peptides are commonly studied together, that the compound is for laboratory research use only and is not for human consumption, that it is not medical advice, and that it is not intended to diagnose, treat, cure, or prevent any disease.
WADA classification means the compound is also prohibited in WADA jurisdiction sports.
07 /Family relationships in the Apothify library
TB-500 sits in the healing and recovery research category alongside BPC-157, Pentadeca Arginate, KPV, AcSDKP, ARA-290, and the Khavinson tissue specific bioregulator series. Most of these are ELEVATED.
Adjacent compounds in cell motility research include the actin binding peptides in the broader cytoskeletal research literature, which Apothify does not list because they are not commonly sourced as research peptides in the consumer or biohacker categories.
08 /What to read next
The BPC-157 overview is the natural complement to this guide and covers the most commonly compared peptide. The Khavinson bioregulator series guide covers a different but adjacent family in tissue recovery research. The how to compare two peptides guide explains how to use the compare tool with these entries.
For the underlying research literature on TB-500 and Thymosin Beta-4, primary sources on PubMed are the place to go. The Apothify entry summarizes; primary sources cover the actual data.
09 /Where the research goes from here
Active research areas include the mechanism of TB-500 across cardiac, ocular, and dermatological tissue models, the regulatory landscape (which has been tightening), and the relationship between rodent and human research on this compound family. The published literature is active but the regulatory environment in the United States has compressed the practical research pathway.
